New Test Announcement

St. Luke's Laboratory Services

HPV High-Risk Screening at St. Luke's

We are pleased to announce that effective September 22, 2010 all human papillomavirus high risk (HPV HR) screening will be performed at St. Luke's Hospital Laboratory using Cervista™ HPV HR. This new methodology is a molecular assay that uses signal DNA amplification technology (Invader Chemistry). Receiving FDA approval in March 2009, this new methodology has incorporated several improvements over previously available HPV tests:

- Detects the presence of 14 oncogenic, high-risk HPV subtypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68).
- Requires less specimen volume, therefore minimizing the number of samples rejected due to "quantity not sufficient."
- Only FDA approved HPV Assay that contains an internal control that detects the presence of human DNA in a sample, thus eliminating false negative results.

Specimen/Transport Requirements:

- Testing will be performed using the Cytyc thin prep pap vials
- HPV testing may be ordered initially or as a reflex test
- Tests may be ordered for up to 10 weeks post collection
- All tests will be ordered in the same way and reported using a very similar format with the same availability in the EMR.

If you have any questions, please contact Sarah J. Lundeen, M.D, Director of Cytopathology at (218) 249-5208, Jennifer Viergutz, MT (ASCP) Technical Specialist of Immunology at (218) 249-5024 or Romine R. Deming, CT (ASCP) Technical Specialist of Cytopathology at (218) 249-5315.

St. Luke's Laboratory Services has a Web page which contains New Test Announcements. http://www.slhduluth.com/hospital/laboratory-services/